Due to improvements in the production of fURSs, flexible ureteroscopy is the preferred method of treating upper urinary tract stones [1, 16]. However, there have consistently been worries about the high price [17]. The price of the flexible ureteroscope technique includes the cost of the laser used for stone fragmentation, the pay of the staff members responsible for cleaning and sterilization procedures, and all accessory tools used during the treatment. Institutions may also encounter severe delays in repairing or exchanging broken re-fURS [16, 17].
On the other hand, su-fURSs may offer solutions for the problems mentioned above, particularly in reducing the cost of repairing and replacing re-fURSs [18]. According to a few randomized controlled trials, FURSs are brittle and necessitate high maintenance and repair expenses [19, 20]. A digital fURS is typically used 21 times before requiring a repair, and a fiber-optic ureteroscope is typically used 6 to 15 times before being returned to its maker [7, 21].
Legemate et al. [22] reported that digital re-fURSs had more extended durability (mean: 27; 20–56) compared to fiber-optic fURSs (mean: 24; 10–37), but the average durability of re-fURSs ranged from 3 to 11 cases [9, 23–25]. Another study concluded that not only are new fURSs
more resistant to malfunction (mean: 44) than refurbished devices, but the new re-furs last longer if they are maintained and repaired by the original maker (mean: 11.1) than by outside contractors (mean: 6.9) [9].
Previous studies have tested the first generation of su-fURSs, but suboptimal surgical effects prevent their inclusion into daily practice [26–28]. However, newer su-fURS provide similar clinical efficacy and maneuverability to reusable scopes and are now part of routine daily practice in urology [13, 29–34]. Since su-fURSs don't need to be repaired, maintained, or sterilized, and the stock is managed by a hospital's pharmacy, one of their key benefits is accessibility and availability [18, 35].
Despite adherence to the decontamination and sterilization processes of reusable ureteroscopes, risks of infection and cross-contamination exist. Ofstead et al. analyzed 16 re-fURS procedures in two different centers, finding that despite disinfection procedures, all the re-fURSs had visible damage and were contaminated with hemoglobin, protein, or microbial growth. There is no such risk with su-fURSs [5].
Various studies have reported on the incidence rate of re-fURS breakage that occurs during storage or processing, finding that 7.7–22% of the time, re-fURSs are damaged even in the hands of qualified staff [8, 21, 26, 29]. Abraham et al. studied two identical fiber-optic re-fURSs that undergo sterilization through different sterilization processes. The first ureteroscope, sterilized with the Steris system, had 297 broken fibers, a 12-mm tear on its shaft, and a 37% loss in resolution after 100 sterilization cycles, according to the authors. Ten damaged fibers were found in the second re-fURS, which had been Cidex sterilized [36].
In our hospital, re-fURS re-sterilization involves three hours of labor and three paramedical personnel, while su-fURSs are stored in a sterile package in the operating room. The su-fURS are delivered to a burning device after each treatment.
The price of buying, repairing, and sterilizing the scope must be factored into the total cost of re- fURSs. A modern re-fURS (Flex-X, Karl Storz, Germany) costs USD 13,611, according to a recent study [37].
In a recent Australian study, the digital Olympus URF-V was purchased for USD 20,200 [15]. The cost of reprocessing this device includes paying employees (nurses, technicians, etc.) and buying supplies for cleaning, sterilization, packaging, and leakage testing. Recent cost analyses indicated that the cost of reprocessing ranged from USD 19.90 to USD 108.00 per case if the price of purchasing a STERRAD machine (a system that uses low-temperature hydrogen peroxide gas plasma technology to sterilize) is not taken into account [15, 37–39].
In the present study, the average cost for re-FURS was approximately SAR 3,668 (USD 975) per case, and the price for su-fURS was approximately SAR 1,650 (USD 438) per case, that did not change from 2022 till end of 2024. Tagushi et al. reported a USD 3.65 recycling cost per re-fURS of the type used in their study [40].
The purchase cost of a su-fURS is always a concerning issue. The business agreement between the manufacturer and the hospital has the most significant impact. LithoVueTM [15, 33, 41], PolyscopeTM [42], and SemiFlexTM [30] have reported purchase prices ranging from USD 1,300 to USD 3,180, USD 700, and USD 800, respectively. More su-fURSs will be well-spent as production technology develops, perhaps lowering final retail pricing. As more manufacturers vie for market share, sales prices could also drop (Sales prices may decrease as more manufacturers compete for market share).
Martin et al. conducted a cost-benefit analysis on all available fURSs to determine the cost of re- fURSs. They reported a cost of USD 848.10 per case and favored the purchase of re-fURSs when more than 99 procedures a year were being performed at a hospital, suggesting that re-fURSs are more cost-effective in high-volume institutions [43]. Similarly, Mager et al. conducted a cost- analysis study to evaluate the expenses of fURSs. The study reported that the cost of re-fURS ranged between USD 436 and USD 708 per case. When the initial purchasing costs were added, the total cost increased to $1,212–USD 1,743 per case. Based on data and studies, LithoVueTM procedures range in price from USD 1,300 (market pricing) to USD 3,180 (manufacturer's recommended wholesale price) per case. Mager et al. discovered in a prediction model that the routine use of su-fURSs would be more costly than the routine usage of re-fURSs after executing 61 to 118 examples [38].
In a German case series, Ozimek et al. reported 321 cases of kidney stone treatment and 102 diagnostic fURS surgeries. On average, 14.4 incidents resulted in scope damage, and all operations cost a total of USD 261,332. The calculated average cost per fURS procedure was USD 617.40. Ozimek et al. concluded that the use of re-fURSs was cost-effective when compared to the use of su-fURSs since the price of a LithoVueTM device was USD 1,227.50 [44].
According to Hennessey et al., the mean cost per case for seven new digital re-fURSs utilized over 30 months was USD 533 (USD 276-USD 904), and the overall repair cost for these devices was USD 124,800. The increasing cost of 28 cases using re-fURSs was USD 38,360. For a su- fURS (LithoVueTM) that costs USD 1,918, the total cost would be USD 55,239 for the same 28 cases; thus, the re-fURSs would be more economical. Conversely, if the cost of su-fURSs were USD 920, then the cost for 28 cases would be USD 26,850, which would be a considerable economic, saving [15].
Study limitation
The present study has some limitation including, the expense of maintaining room sterilization was not considered in the current analysis, which would have increased the price of processing re-fURSs. Another limitation of this study is that the waste processing of su-fURSs was not included in the cost analysis. Additionally, post operative possible infection and its treatment cost that may include hospital readmission were not evaluated in the study.